Physician profile
Jafy John
NPI 1356916464
$2,134.67
in general payments reported to CMS, 2019-2025
24 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $15.74 · 2023: $635 · 2024: $1,252 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,118.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $444.49 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $348.56 | 2023-2025 | |
| Lilly USA, LLC | $129.30 | 2023-2024 | Mounjaro, Trulicity, Jardiance |
| Medtronic, INC. | $126.96 | 2025 | Symplicity G3 |
| Astrazeneca Pharmaceuticals LP | $126.83 | 2023-2024 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $123.13 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $101.92 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $96.66 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $76.31 | 2024 | |
| Amgen INC. | $68.46 | 2023-2024 | Repatha, Otezla |
| Biogen, INC. | $61.11 | 2024 | Skyclarys, Leqembi |
| Otsuka America Pharmaceutical, INC. | $59.39 | 2023 | Rexulti |
| Xeris Pharmaceuticals, INC. | $58.55 | 2023-2024 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $46.13 | 2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.04 | 2023-2024 | Xifaxan |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $34.42 | 2025 | Purified Cortrophin Gel |
| Neurocrine Biosciences, INC. | $29.44 | 2023 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.29 | 2024 | Jardiance |
| Shield Therapeutics INC | $27.15 | 2024 | |
| Janssen Pharmaceuticals, INC | $23.52 | 2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $23.09 | 2024 | |
| Phathom Pharmaceuticals, INC. | $21.46 | 2024 | Voquezna |
| Corium, LLC | $21.43 | 2023 | Azstarys |
| Eisai INC. | $18.03 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jafy John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.